(Stroke. 1999;30:1118-1124.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Anesthesiology (H.S., D.S.W.), Medicine (Neurology) (D.T.L.), and Surgery (R.D.P., D.S.W.), Duke University Medical Center, Durham, NC; Department of Anesthesiology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany (G.B.M.); and the Department of Anesthesiology and Resuscitation, Yamagata University, Yamagata, Japan (M.K.).
Correspondence to David S. Warner, MD, Department of Anesthesiology, Box 3094, Duke University Medical Center, Durham, NC 27710. E-mail warne002{at}mc.duke.edu
| Abstract |
|---|
|
|
|---|
MethodsApoE deficient (n=16) and wild type (n=17) halothane-anesthetized mice were subjected to severe forebrain ischemia (10 minutes of bilateral carotid occlusion and systemic hypotension). After 3 days' recovery, brain injury was determined histologically. In other apoE-deficient and wild-type mice, regional cerebral blood flow (CBF) was determined by 14C-iodoantipyrine autoradiography 10 minutes before, 5 minutes after onset of, and 30 minutes after reperfusion from 10 minutes of forebrain ischemia.
ResultsThe percentage of dead hippocampal CA1 neurons (mean±SD) was greater in the apoE-deficient group (apoE deficient=67±30%; wild type=37±33%; P=0.011). A similar pattern was observed in the caudoputamen (P=0.002) and neocortex (P=0.014). Cerebral blood flow was similar between groups at each measurement interval. Marked hypoperfusion persisted in both groups at 30 minutes after ischemia.
ConclusionsApoE deficiency worsens ischemic outcome. This is not attributable to effects on CBF. A role of apoE in the cerebral response to global ischemia is consistent with prior reports that murine apoE deficiency increases infarct size resulting from focal cerebral ischemia.
Key Words: apolipoproteins cerebral blood flow ischemia histology mice
| Introduction |
|---|
|
|
|---|
To further explore the role of apoE in ischemic brain injury, we previously examined the effects of apoE deficiency in mice subjected to transient middle cerebral artery occlusion (MCAO). ApoE-deficient mice had larger infarct volumes and worse functional outcome than matched wild-type controls.12 This increased susceptibility of apoE-deficient mice to focal ischemia was not a function of differences in intraischemic cerebral blood flow (CBF) or vascular anatomy.13
Although the technique of transient MCAO is an appropriate model for focal ischemia, it does not accurately reflect the pathophysiology after global cerebral hypoperfusion, such as may occur during hemorrhagic shock, cardiac resuscitation, or cardiopulmonary bypass. We have recently characterized a 2-vessel occlusion recovery model of global ischemia in the mouse14 and now demonstrate that apoE-deficient mice are more sensitive to transient global ischemia than control mice matched for age, gender, and genetic background.
| Materials and Methods |
|---|
|
|
|---|
Male mice (8 to 10 weeks of age; apoE deficient, n=16; wild type, n=17) were overnight fasted but allowed free access to water. Mice then were anesthetized with 3% halothane. The trachea was intubated with a 20-gauge intravenous catheter (Insyte-W, Becton Dickinson). The inspired halothane concentration was reduced to 1.2%, and the lungs were mechanically ventilated at a rate of 130 breaths per minute with a delivered tidal volume of 0.7 mL. Pericranial temperature was monitored from a needle thermistor percutaneously placed adjacent to the skull. Temperature was servoregulated at 37.0°C by surface heating or cooling during ischemia and for 30 minutes after reperfusion. Via surgical incision, the right femoral artery was cannulated (PE10, Becton Dickinson) to allow measurement of mean arterial blood pressure (MAP) and blood gases. Heparin (6 IU) was given intravenously. Via surgical incision, the common carotid arteries were identified and encircled with suture. The right internal jugular vein was cannulated to allow drug delivery and blood withdrawal.
Ischemia was induced by intra-arterial infusion of 0.3 mg of trimethaphan camsylate.14 16 As required, blood (0.5 to 0.6 mL) was withdrawn from the venous catheter to maintain MAP at 30±5 mm Hg. The common carotid arteries were then temporarily occluded and a timer was started. Halothane was discontinued. After 10 minutes of ischemia, the carotid arteries were deoccluded and any withdrawn blood was reinfused. NaHCO3 (15 µL of 8.4%) was given intravenously, and the vascular catheters were removed. The wounds were infiltrated with lidocaine and closed with suture. Mice were allowed to recover in an oxygen-enriched environment (fraction of inspired oxygen, 0.5). After recovery of spontaneous ventilation and the righting reflex, the trachea was extubated, and animals were returned to their cages with free access to food and water.
A recovery interval of 3 days was allowed. The mice were then subjected to a neurological examination designed to detect motor deficits in the rat17 that was modified for the mouse. Briefly, the mice were placed on a 10x20-cm screen (grid size 0.2x0.2 cm) that could be rotated from 0° (horizontal) to 90° (vertical). The mouse was placed on the horizontal screen, and the screen was then rotated into the vertical plane. The duration of time that the mouse was able to hold on to the vertical screen was recorded, to a maximum of 15 seconds (allowing a total of 3 points). Next, the mouse was placed at the center of a horizontal wooden rod (1.5 cm in diameter), and the time that the mouse was able to remain balanced on the rod was recorded, to a maximum of 30 seconds (allowing a total of 3 points). Finally, a prehensile traction test was administered. The time that the mouse was able to cling to a horizontal rope was recorded, to a maximum of 5 seconds. From these 3 tests, a total motor score (9 possible points) was computed.
Mice were then anesthetized with halothane, the trachea was intubated, and the lungs were mechanically ventilated. Brains were perfusion fixed in situ with buffered 10% formalin. After overnight stabilization, the brains were removed and stored in 10% formalin. Paraffin-embedded brain sections were serially cut (5 µm thick) and stained with acid fuchsin/celestine blue. With the investigator blinded to the different treatments, injury to the CA1 sector of the hippocampus was evaluated by light microscopy at bregma=-1.70 mm. Viable and nonviable neurons were manually counted, and the percentage of nonviable neurons was calculated (% CA1 dead). At the same anatomic level, damage in the dorsal neocortex was graded using a crude damage index with a scale of 0 to 3 (0=no damaged neurons; 1=1% to 30% neurons damaged; 2=30% to 60% neurons damaged; and 3=>60% of neurons damaged).18 Damage in the dorsolateral caudoputamen was graded using the same scale at bregma=+0.50 mm. Values from the hemisphere with the worst damage were used for the statistical analysis.
For CBF analysis, mice underwent an anesthetic and surgical protocol identical to that described above. In addition, catheters were placed via surgical incision in the left femoral artery and left jugular vein (intraischemic blood flow studies only). One arterial catheter was used for continuous monitoring of MAP. The other arterial catheter was used for collection of timed arterial blood samples. The right jugular vein catheter was used for infusion of isotope. The left jugular catheter was used for withdrawal or infusion of blood as required during ischemia to maintain MAP at 30 mm Hg. Subsets of wild-type and apoE-deficient mice (n=4 to 7 per group) underwent CBF determination 10 minutes before ischemia, at the midpoint of ischemia, or at 30 minutes after onset of reperfusion. Ischemia and reperfusion were produced exactly as described for those animals subjected to histologic outcome analysis.
At the respective CBF measurement intervals, 5 µCi of
4-iodo-n-methyl-[14C]antipyrine in 50 µL saline
(14C-IAP, specific activity 55.4 mCi/mmol, American
Radiolabeled Chemicals, Inc) was infused into the jugular vein over 60
seconds in a 60-step ramp (0.1 µL/min to 203 µL/min) to produce an
increasing 14C-IAP arterial concentration. For
animals in which CBF was measured before or after ischemia,
twelve 10-µL arterial blood samples were collected during
14C-IAP infusion (Unopette capillary pipettes, Becton
Dickinson Co) for later determination of arterial
14C activity. In between sample collections, the
arterial catheter was allowed to bleed freely. The blood
volume lost was
50 µL greater than the volume infused. In
preparing for the study, venous (5 cm PE-10 affixed to 5 cm PE-50) and
arterial (2 cm PE-10) catheters were standardized for
length and volume. For animals in which CBF was measured during
ischemia, arterial blood was continuously withdrawn
from the right femoral artery at a rate of 200 µL/min into a 90-cm
PE-50 catheter. This was required because free flow from the
arterial catheter was negligible when MAP equaled 30
mm Hg (see below). At completion of the experiment, this catheter
containing radioactive blood was sectioned into 6.6-µL increments
(representing 2-second withdrawal intervals sampled at
3-second intervals) for later determination of timed
arterial 14C activity. Simultaneous
with the last blood sample and completion of isotope infusion, all
animals were decapitated and their brains rapidly frozen in
2-methylbutane (-20°C). Arterial blood samples were
placed on filter paper, dried for 24 hours, and then eluted an
additional 24 hours in 1 mL normal saline and 10 mL liquid
scintillation cocktail (CytoScint, ICN). Radioactivity was determined
via liquid scintillation counting using an external quench
correction.
The continuous arterial blood withdrawal method used to define arterial 14C-IAP concentrations in ischemic mice was examined in an in vitro experiment. The estimated blood volume of the mouse is approximately 2 mL.19 Accordingly, a 2-mL sample of rat blood was obtained and placed in a container with a stir bar. Into this blood we infused 14C-IAP at the ramp infusion rate used in the in vivo CBF experiments. Simultaneous with this infusion, blood was sampled by continuous aspiration, exactly as was done in the in vivo experiments. Also simultaneous with the infusion, blood was sampled from the container by micropipette at 5-second intervals which simulated the technique developed by Sakurada et al.20 The samples were then analyzed for 14C-IAP activity using standard scintillation counting techniques. Areas under the respective curves for the 2 sampling techniques were calculated. The area under the curve for the continuous technique (149 988 counts per minute) was 7% less than that of the intermittent (161 388 counts per minute) technique. Thus, the difference between sampling techniques was small, although the continuous sampling technique could theoretically yield flow values less than those provided by the intermittent sampling technique.
Frozen brains were coronally sectioned (20 µm thick) at -16°C. Quadruplicate sections were taken at bregma +1.42, -2.06, -2.30, -3.08, -4.16, and -5.40 mm,21 mounted on glass slides, dried for 5 minutes on a hot plate (36.0°C), and exposed to Kodak SB-5 autoradiographic film for 5 days along with 14C-methylmethacrylate standards (ranging from 0 to 35.0 nCi/mg).
Images from each anatomic level were scanned by a video camera and stored as a 1280x960 matrix of calibrated pixel units (14x15 µm). Digital optical densities from these autoradiographic images, standard radioactivity values derived from 14C standards, and timed arterial blood 14C activity were entered into an image analyzer (MCID-M2, version 3.0 revision 1.2, Imaging Research Inc.). Radioactivity values were converted to CBF values according to the operational equation of Sakurada et al.20 An observer, blinded to experimental group, outlined regions of interest. Regional CBF values were determined from at least three sections and values for each region for each animal were averaged. In addition, a pixel sorting technique was used to define the cross-sectional area of tissue in each region where flow was less than 15 mL/100 g/min.
Neurological scores and Crude Damage Index values for the caudoputamen and cortex were compared between groups by the Mann Whitney U statistic and are expressed as median±interquartile ranges. Physiologic and CBF values and hippocampal percentage of dead CA1 neurons were compared by the unpaired 2-tailed Student t test and are expressed as mean±SD. Significance was assumed with P<0.05.
| Results |
|---|
|
|
|---|
|
|
Physiological values for the CBF study are
summarized in Table 2
. There were no
differences between groups. Regional CBF values are given in Figure 2
. No differences were detected between
genetic groups 10 minutes before, during, or at 30 minutes after
ischemia in the caudoputamen, cortex, hippocampus,
and corpus callosum (not shown). Thalamic blood flow was similar
between groups before and after ischemia, but
intraischemic blood flow was greater in the apoE-deficient
group (P<0.05). As intended, severe blood flow reduction
was restricted to the forebrain with little change in
intraischemic or postischemic blood flow in caudal
structures such as cerebellum and pontine nucleus. Reperfusion at 30
minutes was associated with a persistent state of hypoperfusion in the
caudoputamen, cortex, and hippocampus, with CBF values
recovering to only 45% to 60% of baseline values. There were no
differences between groups for percentage of cross-sectional area where
flow was <15 mL/100 g/min. Prior to ischemia there were
essentially no pixels within this flow bin. During ischemia
>98% of pixels in the hippocampus, caudoputamen, and
neocortex met this criteria. Data from the reperfusion interval is
shown in Figure 3
. Although no
differences between groups were observed, within the hippocampus
20% of tissue met the <15 mL/100 g/min criterion after 30 minutes
of reperfusion.
|
|
|
| Discussion |
|---|
|
|
|---|
The worsened histological outcome observed in the apoE-deficient mice is consistent with a prior investigation that demonstrated worsened neurological/histological outcome from focal ischemia in apoE-deficient mice. Total infarct volume resulting from 60 minutes MCAO and 24 hours' reperfusion was 64% greater in the apoE-deficient group than in the wild-type group.12 Later work showed that both apoE-deficient and wild-type mice are exposed to similar severities of blood flow reduction during MCAO and that the frequency of vascular anomalies in the circle of Willis is similar between apoE-deficient and wild-type groups.13 Further, it has been shown that outcome from murine focal cerebral ischemia is modified by apoE genotype. Mice carrying the human APOE3 transgene (on a murine APOE knockout background) had a 38% reduction in total infarct volume resulting from 60 minutes of MCAO and 24 hours of reperfusion compared with mice expressing the human APOE4 transgene.22 Cumulatively, this evidence provides a strong case for the role of apoE in the pathophysiological response to an ischemic brain insult in the mouse.
We believed that direct measurement of CBF was essential to prove that the severity of the global ischemic insult used in this study was similar between groups. Because apoE plays a central role in lipid transport, a hallmark of apoE deficiency in both the mouse and human is hypercholesterolemia.23 24 This is associated with acceleration of atherosclerosis.25 26 27 However, in the apoE-deficient mouse, microscopic preatherosclerotic lesions do not become apparent until 3 to 4 months of age, with more advanced lesions becoming manifest by 9 to 12 months of age. This would not be expected to appreciably alter blood flow in mice at the age of 8 to 10 weeks as used in the current study and is consistent with the absence of differences in blood flow observed in the apoE-deficient and wild-type groups.
The mechanistic basis by which apoE affects ischemic outcome is unknown. While a definitive answer to this question must await further research, there are known effects of apoE deficiency that may be of relevance. Masliah et al28 reported extensive dendritic vacuolization and disruption of the neuronal cytoskeleton in apoE-deficient mice. Others have observed reduced brain choline acetyltransferase activity in the hippocampus and frontal cortex of apoE-deficient mice. This was correlated with deficits in working but not reference memory29 and is consistent with the finding that hippocampal tissue taken from apoE-deficient animals exhibits reduced in vitro plasticity in response to stimulation of Schaffer/commissural fibers.30 Such effects have been found to be reversible if recombinant apoE is infused intraventricularly.31 ApoE is also known to decrease lymphocyte proliferation and immunoglobulin synthesis of B lymphocytes after mitogenic challenge and suppress glial secretion of inflammatory cytokines,32 suggesting a potential immunomodulatory mechanism.33 ApoE also has the ability to protect neurons from oxidative injury.34 Finally, in the gerbil, apoE is selectively expressed in vulnerable areas of the hippocampus after global ischemia,35 and apoE accumulates in postischemic neurons in the rat.36 37 This suggests a potential active role of apoE in response to events initiated during the ischemic insult. The increasing body of evidence from both human and animal studies that indicates a role for apoE in ischemic injury justifies further study of the mechanisms by which such effects occur.
This study also demonstrates potential value of the murine adaptation of the Lund 2-vessel occlusion plus systemic hypotension (2VO) model, which was originally developed for the rat.14 16 Despite exciting progress in the development of rat genetic mutants for use in ischemia research,38 the mouse is likely to play a significant role in such studies in the foreseeable future. Not only are a wide variety of murine mutants available, but also in some circumstances murine genotypes may be more similar to those found in humans as opposed to those found in rats. For example, mice that either overexpress extracellular superoxide dismutase (EC-SOD) or are EC-SOD deficient have been found to have worsened/improved outcome, respectively, from focal ischemia when compared with wild-type counterparts.39 40 Both murine and human EC-SOD are tetrameric, while that of the rat is dimeric.41 Further, rats express little EC-SOD, while concentrations in the mouse and human are orders of magnitude greater and similar.42 This would suggest that the mouse would be a more appropriate species than the rat for study of EC-SOD in ischemic brain.
The 2VO murine model used in this study has recently been shown to be sensitive to expected effects of preischemic hyperglycemia (worsened damage) and mild hypothermia (neuroprotection).14 An alternative murine model uses bilateral occlusion of the carotid arteries (BCAO) in the absence of systemic hypotension.43 44 45 Intervals of occlusion have been varied from 3 to 75 minutes. In the BCAO model, global ischemia can be studied in the absence of any confounds derived from hemorrhagic shock and often in the absence of an anesthetic agent. At the same time, the BCAO model is limited in application because it requires a similar frequency of atresia in the posterior communicating arteries that must be defined in every experimental group. Different strains of mice have different frequencies of atresia, making interstrain comparisons potentially invalid on the basis of vascular anatomy. Further, the severity of damage is typically mild. Fujii et al43 reported on a semiquantitative analysis of CA1 damage resulting from 20 or 30 minutes of BCAO in C57B1/6 mice. A mean score of approximately 1 (few damaged cells) on a scale of 0 to 4 was reported regardless of duration of ischemia. In contrast, the 2VO model produced an average of 40% dead CA1 neurons with minimal animal mortality. Unpublished work in our laboratory has shown that CA1 damage can be increased to 70% to 80% by increasing the ischemia duration to 12 minutes.
In this model of severe forebrain ischemia, arterial pH was low even before onset of ischemia. We do not know the reason for this but speculate that it was attributable to the halothane anesthetic. Other authors have reported arterial pH in normothermic, normoglycemic anesthetized mice. Yang et al45 report a range of 7.12 to 7.22 under halothane anesthesia. This corresponds to a pH range of 7.15 to 7.17 in our mice, also anesthetized with halothane. In contrast, Fujii et al43 report a pH range of 7.26 to 7.31 in mice subjected to global ischemia, but mice in that study were anesthetized with chloral hydrate. Finally, Sobey and Faraci46 reported values of 7.41±0.01 in mildly hypocapnic mice anesthetized with pentobarbital.
This study does not serve to directly define the effects of human apoE on global ischemic outcome. Murine apoE is only 70% homologous to that of the human.47 Further, although 10 back-crosses of the apoE deficient mutant to the C57/B16J strain had been achieved and >99.99% homology is expected, we cannot be certain that the only difference between the apoE-deficient and wild-type mice is the expression of a single gene. Finally, only 1 isoform for murine apoE has been identified. However, identification of murine apoE deficiency as a determinant of ischemic outcome allows further studies to be performed that can address the effects of human apoE on global ischemic outcome. For example, it can be asked whether acute intracerebroventricular infusion of recombinant human apoE will serve to correct the effects of apoE deficiency on ischemic outcome and whether this restoration of function is apoE isoform and/or dose specific.
In conclusion, mice deficient in apoE were subjected to 10 minutes of severe forebrain ischemia and 3 days of recovery. Histologic outcome was compared to that found in wild-type control mice subjected to the same insult. Increased neuronal necrosis was observed in the apoE-deficient hippocampal CA1, caudoputamen, and neocortex. Cerebral blood flow measured before, during, and 30 minutes after ischemia in cohort animals was found to be similar in the apoE-deficient and wild-type groups. This indicates that the severity of the insult was similar and that specific factors associated with apoE deficiency must account for the observed effect on histological outcome. These data are consistent with prior reports that indicate a role for apoE in ischemic brain injury and justifies further investigation into the mechanisms by which apoE enhances tolerance to brain ischemia.
| Acknowledgments |
|---|
Received October 27, 1998; revision received February 16, 1999; accepted February 17, 1999.
| References |
|---|
|
|
|---|
4 and risk of dementia with stroke, a
population-based investigation. JAMA. 1997;227:818821.
. J
Neuroimmunol. 1997;76:7074.[Medline]
[Order article via Infotrieve]
Laboratory of Cerebrovascular Biology and Stroke, Department of Neurology, University of Minnesota, Minneapolis, Minnesota
| Introduction |
|---|
|
|
|---|
Relatively little is known about the neurobiology of apoE. There is
evidence that apoE and some of the peptides derived from its
proteolytic processing are toxic to neurons in culture.2 3
However, protective effects have also been reported. For example, the
apoE3 isoform mitigates ß-amyloidinduced neurotoxicity in rat
hippocampal neurons.4 The opposing biological actions of
apoE are also underscored by clinical studies indicating that the
4
allele increases whereas the
2 allele decreases the risk for
Alzheimer's disease.5 6 The finding of Sheng et
al that deletion of the APOE gene worsens the outcome of cerebral
ischemia provides additional evidence that selected isoforms of
apoE can be protective.
However, only 1 form of apoE has been identified in mice whereas 3 isoforms are known to exist in humans.7 Therefore, it remains unclear how experimental evidence obtained in mouse models relates to the biology of apoE in human diseases. Nonetheless, the elegant study of Sheng et al, in concert with previous studies by the same group, suggest strongly that apoE protects the brain from the consequences of cerebral ischemia. The mechanisms by which apoE modulates brain damage and the role of apoE in the overall process of ischemic brain injury, in rodents as in humans, remain to be defined.
Received October 27, 1998; revision received February 16, 1999; accepted February 17, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Hayashi, R. B. Campenot, D. E. Vance, and J. E. Vance Apolipoprotein E-Containing Lipoproteins Protect Neurons from Apoptosis via a Signaling Pathway Involving Low-Density Lipoprotein Receptor-Related Protein-1 J. Neurosci., February 21, 2007; 27(8): 1933 - 1941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rotstein, H. Bassan, N. Kariv, Z. Speiser, S. Harel, and I. Gozes NAP Enhances Neurodevelopment of Newborn Apolipoprotein E-Deficient Mice Subjected to Hypoxia J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 332 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Lane and M. R. Farlow Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease J. Lipid Res., May 1, 2005; 46(5): 949 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-i. Ito, Y. Nagayasu, R. Lu, A. Kheirollah, M. Hayashi, and S. Yokoyama Astrocytes produce and secrete FGF-1, which promotes the production of apoE-HDL in a manner of autocrine action J. Lipid Res., April 1, 2005; 46(4): 679 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Diaz-Arrastia, Y. Gong, S. Fair, K. D. Scott, M. C. Garcia, M. C. Carlile, M. A. Agostini, and P. C. Van Ness Increased Risk of Late Posttraumatic Seizures Associated With Inheritance of APOE{epsilon}4 Allele Arch Neurol, June 1, 2003; 60(6): 818 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Paradis, S. Clement, P. Julien, and M. R. Ven Murthy Lipoprotein Lipase Affects the Survival and Differentiation of Neural Cells Exposed to Very Low Density Lipoprotein J. Biol. Chem., March 7, 2003; 278(11): 9698 - 9705. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koistinaho, M. I. Kettunen, D. M. Holtzman, R. A. Kauppinen, L. S. Higgins, and J. Koistinaho Expression of Human Apolipoprotein E Downregulates Amyloid Precursor Protein-Induced Ischemic Susceptibility Stroke, July 1, 2002; 33(7): 1905 - 1910. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gallagher-Thompson, R. O'Hara, A. Simmons, H. C. Kraemer, and G. M. Murphy Jr Apolipoprotein E isin4 Allele Affects the Relationship between Stress and Depression in Caregivers of Patients with Alzheimer's Disease J Geriatr Psychiatry Neurol, September 1, 2001; 14(3): 115 - 119. [Abstract] [PDF] |
||||
![]() |
L. K. Ti, J. P. Mathew, G. B. Mackensen, H. P. Grocott, W. D. White, J. G. Reves, and M. F. Newman Effect of Apolipoprotein E Genotype on Cerebral Autoregulation During Cardiopulmonary Bypass Stroke, July 1, 2001; 32(7): 1514 - 1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O. McCarron, K. W. Muir, J. A. R. Nicoll, J. Stewart, Y. Currie, K. Brown, and I. Bone Prospective Study of Apolipoprotein E Genotype and Functional Outcome Following Ischemic Stroke Arch Neurol, October 1, 2000; 57(10): 1480 - 1484. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||